Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stargardt Disease Clear all
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

NCT07439887
View directory record Official record
Conditions
Stargardt Disease
Interventions
RTx-021
Genetic
Lead sponsor
Ray Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Bakersfield, California • Pittsburgh, Pennsylvania • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

NCT07161544
View directory record Official record
Conditions
Stargardt Disease
Interventions
AAVB-039
Biological
Lead sponsor
AAVantgarde Bio Srl
Industry
Eligibility
8 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting No phase listed Observational

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

NCT06435000
View directory record Official record
Conditions
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Interventions
Not listed
Lead sponsor
Splice Bio
Industry
Eligibility
12 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
San Diego, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rod and Cone Mediated Function in Retinal Disease

NCT02617966
View directory record Official record
Conditions
Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
View directory record Official record
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy

NCT00060749
View directory record Official record
Conditions
Macular Degeneration
Interventions
Docosahexaenoic Acid (DHA) Dietary Supplement
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

Study of STG-001 in Subjects With Stargardt Disease

NCT04489511
View directory record Official record
Conditions
Stargardt Disease-1
Interventions
STG-001
Drug
Lead sponsor
Stargazer Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Gainesville, Florida • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

NCT03364153
View directory record Official record
Conditions
Stargardt's Macular Dystrophy
Interventions
avacincaptad pegol, Sham
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting No phase listed Observational

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

NCT07425574
View directory record Official record
Conditions
Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
Interventions
No Intervention
Other
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
6 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Phoenix, Arizona • Palo Alto, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting No phase listed Observational

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

NCT01145196
View directory record Official record
Conditions
Genotype, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Completed No phase listed Observational Results available

A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies

NCT01977846
View directory record Official record
Conditions
Stargardt Disease
Interventions
Not listed
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
6 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Baltimore, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting No phase listed Observational

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

NCT06375239
View directory record Official record
Conditions
Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
Interventions
Not listed
Lead sponsor
Ray Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

NCT06467344
View directory record Official record
Conditions
Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Interventions
ACDN-01
Drug
Lead sponsor
Ascidian Therapeutics, Inc
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
10
States / cities
San Francisco, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 23, 2026, 2:20 PM EDT
Terminated No phase listed Observational

Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease

NCT01676766
View directory record Official record
Conditions
Stargardt Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting No phase listed Observational

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

NCT07502664
View directory record Official record
Conditions
Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration, X-linked Retinoschisis, Retinal Dystrophies
Interventions
Not listed
Lead sponsor
Ray Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 23, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Emixustat in Stargardt Disease

NCT03772665
View directory record Official record
Conditions
Stargardt Disease
Interventions
Emixustat, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
16 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Beverly Hills, California • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jul 23, 2026, 2:20 PM EDT
Completed No phase listed Observational

The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy

NCT02410122
View directory record Official record
Conditions
Stargardt Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Jul 23, 2026, 2:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

NCT06805474
View directory record Official record
Conditions
Macular Degeneration, Geographic Atrophy, Stargardt Disease
Interventions
Observational
Other
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jul 23, 2026, 2:20 PM EDT